Clinical Research
BibTex RIS Cite

Obstetrics and fetal outcomes in pregnant women with beta-blocker treatment in maternal arrhythmia

Year 2024, Volume: 21 Issue: 1, 8 - 12, 01.04.2024
https://doi.org/10.38136/jgon.1275121

Abstract

Aim: The aim of this study was to investigate the pregnancy prognosis of patients taking beta-blockers for the treatment of cardiac arrhythmias.
Materials and Method: This study was a retrospective observational study involving 50 pregnant women with cardiac arrhythmias and 55 healthy pregnant women, admitted between January 1, 2020 and January 1, 2022, to Ankara City Hospital. Beta-blockers were classified into three groups: metaprolol, propranolol, and bisoprolol. The use of beta-blockers was examined in two groups: high-dose and low-dose. For pregnancy outcome, birth week, birth weight and birth weight Z-score, the bHCG MoM and PAPP-A MoM, neonatal APGAR score, and neonatal intensive care unit admission rates were determined. Statistical analysis was performed using IBM SPSS Statistics 26.0 (IBM Corp, Armonk, NY, USA). Shapiro-Wilk and Kolmogorov-Smirnov tests were both used to evaluate normality of variables. Groups were compared using the Student t-test and the Mann-Whitney U test. P-values < 0.05 were considered as statistically significant.
Results: The patient group taking beta-blockers had a statistically significant earlier delivery week than the group without beta-blocker use (p=0.000). The rate of primary cesarean deliveries was higher in the study group (p=0.007). Birth weight and APGAR score at the fifth minute was significantly lower in the study group, and NICU admission rate was significantly higher (p=0.006, p=0.000 and p=0.000, respectively).
Conclusion: Beta-blockers, a first-line therapy for maternal arrhythmias, may affect fetal development and pregnancy outcomes. İt is recommended that these drugs to be administered are meticulously selected for appropriate subgroups, with lowest effective doses

References

  • (1) Burkart TA, Conti JB, Cardiac arrhythmias during preg- nancy. Curr Treat Options Cardiovasc Med 2010 Oct;12(5):457- 71 (2) van Weerd JH, Christoffels VM, The formation and function of the cardiac conduction system. Development. 2016 Jan 15;143(2):197-210 (3) Carruth JE, Mivis SB, Brogan DR, Wenger NK, The electrocardiogram in normal pregnancy. Am Heart J. 1981 Dec;102(6 Pt 1):1075-8

Obstetrics and fetal outcomes in pregnant women with beta-blocker treatment in maternal arrhythmia

Year 2024, Volume: 21 Issue: 1, 8 - 12, 01.04.2024
https://doi.org/10.38136/jgon.1275121

Abstract

Aim: The aim of this study was to investigate the pregnancy prognosis of patients taking beta-blockers for the treatment of cardiac arrhythmias.
Materials and Method: This study was a retrospective observational study involving 50 pregnant women with cardiac arrhythmias and 55 healthy pregnant women, admitted between January 1, 2020 and January 1, 2022, to Ankara City Hospital. Beta-blockers were classified into three groups: metaprolol, propranolol, and bisoprolol. The use of beta-blockers was examined in two groups: high-dose and low-dose. For pregnancy outcome, birth week, birth weight and birth weight Z-score, the bHCG MoM and PAPP-A MoM, neonatal APGAR score, and neonatal intensive care unit admission rates were determined. Statistical analysis was performed using IBM SPSS Statistics 26.0 (IBM Corp, Armonk, NY, USA). Shapiro-Wilk and Kolmogorov-Smirnov tests were both used to evaluate normality of variables. Groups were compared using the Student t-test and the Mann-Whitney U test. P-values < 0.05 were considered as statistically significant.
Results: The patient group taking beta-blockers had a statistically significant earlier delivery week than the group without beta-blocker use (p=0.000). The rate of primary cesarean deliveries was higher in the study group (p=0.007). Birth weight and APGAR score at the fifth minute was significantly lower in the study group, and NICU admission rate was significantly higher (p=0.006, p=0.000 and p=0.000, respectively).
Conclusion: Beta-blockers, a first-line therapy for maternal arrhythmias, may affect fetal development and pregnancy outcomes. İt is recommended that these drugs to be administered are meticulously selected for appropriate subgroups, with lowest effective doses

References

  • (1) Burkart TA, Conti JB, Cardiac arrhythmias during preg- nancy. Curr Treat Options Cardiovasc Med 2010 Oct;12(5):457- 71 (2) van Weerd JH, Christoffels VM, The formation and function of the cardiac conduction system. Development. 2016 Jan 15;143(2):197-210 (3) Carruth JE, Mivis SB, Brogan DR, Wenger NK, The electrocardiogram in normal pregnancy. Am Heart J. 1981 Dec;102(6 Pt 1):1075-8
There are 1 citations in total.

Details

Primary Language English
Subjects Obstetrics and Gynaecology
Journal Section Research Articles
Authors

Betül Akgün Aktaş 0000-0003-4523-011X

Petek Feriha Uzuner 0000-0002-9260-1780

Atakan Tanacan 0000-0001-8209-8248

Dilek Sahin 0000-0001-8567-9048

Publication Date April 1, 2024
Submission Date April 3, 2023
Acceptance Date November 25, 2023
Published in Issue Year 2024 Volume: 21 Issue: 1

Cite

Vancouver Akgün Aktaş B, Uzuner PF, Tanacan A, Sahin D. Obstetrics and fetal outcomes in pregnant women with beta-blocker treatment in maternal arrhythmia. JGON. 2024;21(1):8-12.